NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Obsidian Therapeutics

Obsidian Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://obsidiantx.com/

Last Round

Private Equity

Apr 14, 2026

Est. Valuation

$763.5M

Total Funding Raised

$325M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Obsidian Therapeutics is a biotechnology company that develops engineered cell and gene therapies for cancer treatment using a proprietary protein-regulation platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

tumor-infiltrating lymphocyteTIL therapycell therapysolid tumor treatmentengineered cell therapyprotein expression regulationbiotechclinical-stage biotechimmunotherapymelanoma treatmentdrug discoveryprecision medicineclinical trialsnext-gen cell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Obsidian Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Obsidian Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Obsidian Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityApr 14, 2026
Series CApr 3, 2024
Series BSep 9, 2021
Series ADec 6, 2017

Key People

Founding team and executive leadership

Madan Jagasia

Chief Executive Officer

Executive Team

Obsidian Therapeutics Investors

Notable investors and investment history

Obsidian Therapeutics investors
InvestorRounds
Redmile GroupPrivate Equity
Soleus CapitalSeries B
Surveyor CapitalSeries C, Series B
Janus Henderson GroupSeries C, Private Equity
Balyasny Asset Management L.P.Private Equity
RA Capital ManagementSeries C, Series B, Private Equity
TCG CrossoverSeries C, Private Equity, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    All-stock merger agreement with Galera Therapeutics announced.

  • Apr 14, 2026

    $350M raised in a Private Placement round.

Obsidian Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Obsidian Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Obsidian Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range106
Year Founded2015
Last FundingApr 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.